Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Harmony Biosciences Holdings Inc shares valued at $202,009 were purchased by JEFFREY G DIERKS on Jun 10 ’25. At $35.98 per share, JEFFREY G DIERKS acquired 5,615 shares.
Also, JEFFREY G DIERKS purchased 9,844 shares, netting a total of over 350,083 in proceeds.
Before that, JEFFREY G DIERKS had added 2,292 shares to its account. In a trade valued at $80,427, the Former Officer bought Harmony Biosciences Holdings Inc shares for $35.09 each.
Analysts at Deutsche Bank started covering the stock with ‘”a Buy”‘ outlook in a report released in mid February. As of December 17, 2024, H.C. Wainwright has initiated its “Buy” rating for HRMY.
Analyzing HRMY Stock Performance
On last trading session,, Harmony Biosciences Holdings Inc [NASDAQ: HRMY] rose 0.03% to $32.48. During the last five days, there has been a drop of approximately -7.57%. Over the course of the year, Harmony Biosciences Holdings Inc shares have dropped approximately -5.61%. Shares of the company reached a 52-week high of $40.93 on 01/21/25 and a 52-week low of $26.47 on 04/09/25.
Support And Resistance Levels for Harmony Biosciences Holdings Inc (HRMY)
According to the 24-hour chart, there is a support level at 32.05, which, if violated, would cause prices to drop to 31.62. In the upper region, resistance lies at 32.86. The next price resistance is at 33.24. RSI (Relative Strength Index) is 40.17 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Harmony Biosciences Holdings Inc (HRMY)?
In terms of Harmony Biosciences Holdings Inc share price expectations, FactSet research, analysts set an average price target of 48 in the next 12 months, up nearly 47.83% from the previous closing price of $32.47. Analysts anticipate Harmony Biosciences Holdings Inc stock to reach 48 by 2025, with the lowest price target being 48. In spite of this, 6 analysts ranked Harmony Biosciences Holdings Inc stock as Buy at the end of 2025. On September 10, 2024, UBS assigned a price target of “a Buy” to the stock and initiated coverage with a $56.
